在HCV诱导的肝细胞癌中,分子和临床方法的系统整合
Ciniso Sylvester Shabangu1,2, Wen-Hsiu Su3,4, Chia-Yang Li1
1Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Journal of translational medicine
|March 13, 2024
概括
持久性型肝炎病毒 (HCV) 感染高调瘤抑制微RNAs (miRNAs),抑制肝癌 (HCC) 的瘤基因. 特定的miRNA及其标RCN1可以作为监测HCV-HCC进展的生物标志物.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 病毒学 病毒学
背景情况:
- 微RNAs (miRNAs) 是基因表达的关键调节者.
- 失调的miRNA功能与诸如C型肝炎病毒 (HCV) 相关的肝细胞癌 (HCC) 等疾病有关.
- 在HCV-HCC中miRNAs和mRNAs之间的调控相互作用仍然不完全理解.
研究的目的:
- 研究持续的HCV诱导miRNA表达对HCC基因调节的功能影响.
- 为了确定特定的miRNA及其mRNA点,参与HCV诱导的肝癌.
主要方法:
- 使用数组数据对miRNAs的差异表达分析.
- 生物信息分析包括DIANA,KEGG途径,基因本体学 (GO) 和发明途径分析 (IPA).
- 在肝肝细胞癌 (LIHC) 瘤中对miRNA-mRNA相互作用的生存分析和调查.
主要成果:
- 确定了17种 (L-HCV) 和9种 (S-HCV) 差异表达的miRNA,每组5种在LIHC瘤中显著表达.
- 由HCV诱导的miRNA与LIHC的生存相关,并调节病毒致癌和细胞循环途径.
- 通过MiRNA介导的RCN1抑制抑制了HCC细胞的入侵和迁移.
结论:
- 持续的HCV感染会诱导抑制瘤的miRNAs,这些miRNAs会抑制HCC中的瘤基因.
- 在miRNA上调和RCN1抑制之间观察到一个反向关系.
- 特定的miRNAs (hsa-miR-215-5p,hsa-miR-10b-5p,hsa-let-7a-5p) 和RCN1显示出作为监测HCV-HCC进展的生物标志物的潜力.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.9K
08:40A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
Published on: August 7, 2020
6.2K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
